The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN study.
 
Tony Mok
Employment - The Chinese University of Hong Kong
Leadership - AstraZeneca; Aurora Tele-Oncology Platform; Epoh; HUTCHMED; Insighta Holdings Limited
Stock and Other Ownership Interests - Alentis Therapeutics; AstraZeneca; Aurora Tele-Oncology Platform; Biolidics; D3 Bio; HUTCHMED; Lunit; Prenetics
Honoraria - Abbvie; ACEA Pharmaceutical Research; Adagene; Alentis Therapeutics; Alpha Biopharma; Amgen; Amoy Diagnostics; AnHeart Therapeutics; AstraZeneca; AVEO; BeiGene; Berry Oncology; Blueprint Medicines; BMS; Boehringer Ingelheim; Bristol-Myers Squibb; C4 Therapeutics; CK Life Sciences Int’l., (Holdings) Inc.; CStone Pharmaceuticals; Curio Science; D3; Da Volterra; Daiichi Sankyo/UCB Japan; Daz Group; Eisai; Fishawack Facilitate; Gilead Sciences; GLG’s Healthcare; Gritstone Bio; Guardant Health; Hengrui Therapeutics; Ignyta; Illumina; Incyte; Inivata; InMed; IQVIA; Janssen; Jiahui Holdings Co; Lakeshore Biotechnology; Lilly; Lucence; Lucence; MD Health Brazil,; Medscape; Merck; Merck Sharp & Dohme; MiRXES; More Health; Ningbo NewBay Medical Technology; Novartis; Novocure; Omega Therapeutics; Origimed; PeerVoice; Permanyer Publications; Pfizer; Phanes Therapeutics; Physicans' Education Resource; Pierre Fabre Group Dermo-Cosmétique Hong-Kong Limited; Prenetics; Prime Oncology; Qiming Development (HK) Ltd.; Regeneron; Research to Practice; Roche; Roche; Sanofi Aventis GmbH; Schrodinger; SFJ Pharmaceutical Ltd; Shanghai BeBirds Translation & Consulting; Shanghai Promedican Pharmaceuticals Co., Ltd; Simcere of America Inc.; Summit Therapeutics Sub, Inc.; Suzhou Liangyihui Network Technology; Synergy Research; Taiho Pharmaceutical; Takeda; Tigermed; touchIME; Vertex; Virtus Medical Group; Xencor; Yuhan
Consulting or Advisory Role - Abbvie; ACEA Pharmaceutical Research; Alentis Therapeutics; Alpha Biopharma; Amgen; Amoy Diagnostics; AstraZeneca; BeiGene; BerGenBio; Berry Oncology; Boehringer Ingelheim; Bowtie Life Insurance Company; Bridgebio; Bristol-Myers Squibb; C4 Therapeutics; Covidien/Medtronic; CStone Pharmaceuticals; D3; Da Volterra; Daiichi Sankyo/UCB Japan; Eisai; Fishawack Facilitate; G1 Therapeutics; geneDecode; Genentech; Gilead Sciences; Gritstone Bio; Guardant Health; Hengrui Therapeutics; HUTCHMED; Ignyta; Imagene AI Ltd.; Incyte; Inivata; Inivata; IQvia; Janssen; Lakeshore Biotechnology; Lilly; Loxo; Lunit; Medtronic; Merck Serono; Merck Sharp & Dohme; Mirati Therapeutics; MiRXES; MiRXES Group; Novartis; Omega Therapeutics; OrigiMed; OrigiMed; OSE Immunotherapeutics; Pfizer; Prenetics; Prenetics; Puma Biotechnology; Regeneron; Roche; SFJ Pharmaceuticals Group; Simcere; Summit Therapeutics, Inc.; Synergy Research; Takeda; Vertex; Virtus Medical Group; Yuhan
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); SFJ Pharmaceuticals Group (Inst); Takeda (Inst); Xcovery (Inst)
Travel, Accommodations, Expenses - Abbvie; Astrazeneca; Beijing Health Promotion Association, China Medical and Pharmaceutical Education Association; Daiichi Sankyo; ESMO; Liangyihui; MiRXES; MSD; Novartis; Pfizer; Pfizer; Roche; TASLC; Zai Lab
 
Benjamin Solomon
Honoraria - Amgen (Inst); AstraZeneca; Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech
Consulting or Advisory Role - Amgen; AstraZeneca (Inst); BeiGene; Bristol-Myers Squibb (Inst); GlaxoSmithKline; GlaxoSmithKline (Inst); Johnson & Johnson/Janssen; Lilly; Merck Sharp & Dohme; Nuvalent, Inc.; Pfizer (Inst); Roche/Genentech (Inst); Takeda
Patents, Royalties, Other Intellectual Property - UpToDate
 
Enriqueta Felip
Honoraria - Amgen; Daiichi Sankyo Europe GmbH; Gilead Sciences; Janssen / Johnson & Johnson; Lilly; MSD; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; Genentech/Roche; GlaxoSmithKline; ITeos Therapeutics; Johnson & Johnson/Janssen; Merck Sharp & Dohme; Pfizer; PharmaMar; Pierre Fabre; Regeneron; Seagen; Tubulis GmbH
Other Relationship - GRIFOLS
(OPTIONAL) Uncompensated Relationships - "ETOP IBCSG Partners" Member of the Scientific Committee; Member of the Scientific Advisory Committee -Hospital Universitari Parc Taulí-; SEOM (Sociedad Española de Oncología Médica), President from 2021-2023
 
Todd Bauer
Employment - Tennessee Oncology
Leadership - Tennessee Oncology
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Lilly; Nuvalent, Inc.; Pfizer
Speakers' Bureau - Foundation Medicine
Travel, Accommodations, Expenses - Pfizer
 
Geoffrey Liu
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; emd serono; Jazz Pharmaceuticals; Merck; novartis; nuvation bio; pfizer; Roche Canada; Takeda
Consulting or Advisory Role - AstraZeneca/MedImmune; novartis; pfizer; Roche Canada; takeda
Speakers' Bureau - AstraZeneca; Pfizer; Takeda
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim; roche (Inst); Takeda
 
Yasushi Goto
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/UCB Japan; Janssen; Lilly Japan; Merck; MSD; Nichiiko; Novartis; Ono Pharmaceutical; Pfizer; Sandoz; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; Towa Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Janssen; Jazz Pharmaceuticals; Kyowa Kirin International; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Summit Health; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Amgen BioPharama (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); CMIC (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo/UCB Japan (Inst); EP Croit Co. (Inst); EPS Holdings (Inst); Genomic Health (Inst); IQvia (Inst); Janssen (Inst); Lilly Japan (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Preferred Network (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
(OPTIONAL) Uncompensated Relationships - Cancer Net Japan; JAMT
 
Yi-Long Wu
Honoraria - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)
 
Ross Soo
Honoraria - Abbvie; Agilent; Amgen; Anheart Therapeutics; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Genmab; J Ints Bio; Johnson & Johnson/Janssen; Lilly; Merck; Merck Serono; Novartis; Novartis; Pfizer; Puma Biotechnology; Roche/Genentech; Sanofi; Taiho Oncology; Takeda; Takeda; Thermo Fisher Scientific; Yuhan
Consulting or Advisory Role - Amgen; Anheart Therapeutics; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; J Ints Bio; Janssen; Lilly; Merck; Merck Serono; Novartis; Pfizer; Puma Biotechnology; Roche/Genentech; Sanofi; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific; Yuhan
Research Funding - AstraZeneca; Boehringer Ingelheim; Pfizer
 
Julien Mazieres
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly/ImClone; MSD; Pfizer; Pierre Fabre; Revolution Medicines; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; MSD; Pfizer
 
Filippo de Marinis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; DAICHII SANKYO; Merck Serono; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Takeda
 
Dong-Wan Kim
Research Funding - Alpha Biopharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); BridgeBio Pharma (Inst); Chong Kun Dang Pharmaceutical (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); IMBdx (Inst); inno.N (Inst); Janssen (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst); TP Therapeutics (Inst); Xcovery (Inst); Yuhan (Inst); Zymeworks (Inst)
Other Relationship - Amgen; AstraZeneca; BMS; Boehringer Ingelheim; BridgeBioTherapeutics; Chong Keun Dang; Daiichi Sankyo; GlaxoSmithKline; IMBdx; Johnson & Johnson/Janssen; Merck; Merck; Merus NV; Mirati Therapeutics; MSD; Novartis; Pfizer; Roche/Genentech; Takeda; Yuhan; Zymeworks
 
I-Ming Wang
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Jolanda Paolini
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Anna Polli
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Nada Rifi
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Francesca Toffalorio
Employment - Pfizer'
Stock and Other Ownership Interests - Pfizer'
 
Alice Shaw
Employment - Amgen (I); Novartis Institutes for BioMedical Research
Stock and Other Ownership Interests - Novartis Institutes for BioMedical Research
Consulting or Advisory Role - Alterome Therapeutics; Astellas Pharma; Bridgebio; Genentech/Roche; Merck; Novartis; Nuvalent, Inc.; Pfizer; Revolution Medicines; Rigel; Tango Therapeutics; Triana
Research Funding - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Amgen; Amgen (I); Novartis Institutes for BioMedical Research
Other Relationship - EcoR1 Capital; Nextech Invest